Polymorphism of the IgH Locus Regulatory Region as a Prognostic Factor During Immune Pathologies.

NCT ID: NCT01715623

Last Updated: 2019-01-22

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

486 participants

Study Classification

OBSERVATIONAL

Study Start Date

2012-10-31

Study Completion Date

2014-12-16

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The investigators previously showed that both antibody class switching (from IgM to IgG, IgA or IgE) and antibody secretion are controlled by a polymorphic "3' regulatory region" (3'RR) of the immunoglobulin heavy chain (IgH) locus. Alleles of the 3'RR have shown influences on the severity and progression of IgA nephropathy (IgAN) (with an over-representation of the B allele among patients with severe kidney IgA deposits). Allele B also constitutes a risk factor for celiac disease, herpetiform dermatitis, psoriasis and rheumatoid arthritis. Since the 3'RR now appears as a crucial regulator of Ig production, we wish to check whether its genetic polymorphism might influence not only the occurrence of immunopathologic processes involving class-switched antibody deregulated production but also the severity of such diseases or the time course of their progression. We wish to focus on two conditions involving class-switched antibodies: on one hand the severe forms of IgE hypersensitivities, and on the other hand a disease involving pathogenic IgA and for which the prognosis is currently very difficult to predict at the onset of the disease: Henoch-Schonlein purpura (HSP).

Regarding hypersensitivities, the diversity of their clinical manifestations prompt us to focus on homogeneous groups of patients and we thus wish to concentrate on two groups of patients who are frequently referred to the hospital: severe allergies to Hymenoptera venoms and severe food allergies related to peanut allergens sensitization. These groups will be built by considering multiple clinical criteria (clinical history, severity of the manifestations, positive skin tests, and positive oral provocation tests for peanut allergens…) and biological criteria authenticating the mechanisms of the disease (high specific serum IgE, demonstration of specific basophil activation by the allergen…).

In parallel to the study in patients, we will include a large cohort of healthy controls (400 individuals), in order to be able to decipher whether correlations can be seen between:

* IgH 3'RR genotypes
* The serum accumulation of the various Ig classes, including IgG subclasses, IgA (which are sometimes depicted as protective, sometimes as tolerogenic and anti-inflammatory) and IgE (highly pro-inflammatory and responsible for hypersensitivities)
* IgG allotypes (with 6 frequent IgG haplotypes known in human and previously reported as correlated with varying levels of IgG and IgE production in normal individuals).

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This study should thus finally provide answers to 5 questions which are currently un-addressed:

* How the 3'RR alleles are linked to IgG allotypes and corresponding IgH haplotypes?
* Is there a physiological link between 3'RR alleles and production of the various Ig classes and sub-classes?
* Is the 3'RR polymorphism connected with the risk of more severe forms of allergic diseases?
* Is the 3'RR polymorphism connected with the risk of occurrence and/or severe evolution of HSP?
* Is the oncogenicity of translocations affecting the IgH locus connected to the strength of the 3'RR allelic variants?

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Healthy Volunteers Children With HSP Subject With Allergy Lymphoma

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Children with HSP

children with Purpura of Henoch-Schönlein with or without renal complication

a blood sample

Intervention Type BIOLOGICAL

Dosage of Ig

healthy volunteers

healthy volunteers without allergy

a blood sample

Intervention Type BIOLOGICAL

Dosage of Ig

subjects with allergy

subjects with peanut allergy or hymenoptera venom allergy

a blood sample

Intervention Type BIOLOGICAL

Dosage of Ig

lymphoma

lymphoma-proliferation with chromosome 14 translocation

a blood sample

Intervention Type BIOLOGICAL

Dosage of Ig

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

a blood sample

Dosage of Ig

Intervention Type BIOLOGICAL

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Healthy Volunteers:

Age ≥ 18 and \< 50 years No history of allergy, haematological malignancies or immune diseases

* Subjects with allergy:
* Children:

Age ≥ 4 and \< 18 years Clinical history supporting the diagnosis of severe food allergy Peanut specific IgE (Arah2) -Adults: Age \> 18 and \< 60 years History of severe reaction after antigenic challenge Anaphylactic shock already experienced Specific IgE or positive BAT Positive prick tests

* subject with HPS:
* Children:

Age ≥ 4 and \< 18 years Henoch Schonlein Purpura (HSP) documented by Ankara 2008 criteria

-Adult: Henoch Schonlein Purpura(HSP) with renal involvement Adults ≥ 18 years,

Exclusion Criteria

* subject with allergy or subject with Henoch Schonlein Purpura(HSP): known pregnancy patient under guardianship
* Healthy Volunteers:

Allergy known pregnancy patient under guardianship
Minimum Eligible Age

4 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Institut National de la Santé Et de la Recherche Médicale, France

OTHER_GOV

Sponsor Role collaborator

Direction Générale de la Santé, France

OTHER

Sponsor Role collaborator

University Hospital, Limoges

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Michel COGNE, MD

Role: PRINCIPAL_INVESTIGATOR

Limoges UH

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Clinical Investigation Center

Limoges, , France

Site Status

Nephrology

Limoges, , France

Site Status

Pediatric

Limoges, , France

Site Status

Pneumology

Limoges, , France

Site Status

Countries

Review the countries where the study has at least one active or historical site.

France

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

I12002 PRIERR

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Autoimmune Hepatitis Study
NCT00286663 TERMINATED